Physician profile
Diane G Portman
NPI 1437227345
$1,624.72
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $814 · 2023: $737 · 2024: $74.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $153.32 | 2022-2023 | Kyprolis, Blincyto |
| Incyte Corporation | $142.07 | 2022-2023 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $117.02 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $102.47 | 2022-2024 | |
| Eisai INC. | $97.43 | 2022-2023 | |
| Janssen Biotech, INC. | $94.23 | 2022-2023 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $72.23 | 2023 | Lynparza, Enhertu |
| Genzyme Corporation | $72.12 | 2022-2024 | |
| Exelixis INC. | $70.27 | 2022-2023 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $68.25 | 2022-2023 | Ninlaro |
| Karyopharm Therapeutics INC. | $51.07 | 2022-2023 | Xpovio |
| Celgene Corporation | $49.14 | 2022-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $46.54 | 2022-2023 | Keytruda |
| Lilly USA, LLC | $43.85 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Servier Pharmaceuticals LLC | $40.06 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $38.29 | 2023 | Bavencio |
| Puma Biotechnology, INC. | $36.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.87 | 2022-2023 | |
| Seagen INC. | $33.10 | 2023 | Tukysa, Adcetris |
| Alexion Pharmaceuticals, INC. | $30.89 | 2022 | |
| Taiho Oncology, INC. | $28.82 | 2022 | |
| Deciphera Pharmaceuticals INC. | $23.65 | 2023 | Qinlock |
| Stemline Therapeutics INC. | $21.14 | 2024 | Orserdu |
| Eusa Pharma (US) LLC | $18.91 | 2022 | |
| Daiichi Sankyo INC. | $18.44 | 2023 | Enhertu |
| Pfizer INC. | $18.12 | 2022 | |
| G1 Therapeutics, INC. | $17.80 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.23 | 2022 | |
| Apellis Pharmaceuticals, INC. | $15.08 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $13.80 | 2023 | Imbruvica |
| Cti Biopharma Corp. | $13.72 | 2022 | |
| Morphosys, US INC. | $13.48 | 2022 | |
| Mylan Institutional INC. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Portman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.